EEF1A2 overexpression has generally been associated with poorer prognosis in pancreatic ductal adenocarcinoma, non-small cell lung carcinoma, and ovarian cancer patients [15–17]. This evidence concerns the gene EEF1A2 and pancreatic ductal adenocarcinoma.